Table 1.

Patient demographics and baseline disease characteristics.

Total
(N = 63)
Females, n (%)42 (66.7)
Median age, years (range)61.0 (38–80)
Race, n (%)a
 White40 (63.5)
 Asian2 (3.2)
ECOG performance status, n (%)
 022 (34.9)
 133 (52.4)
 28 (12.7)
Lymphoma cohort, n33
 Histology, n (%)
  DLBCL18 (54.5)
   Malignant DLBCL—not otherwise specified15 (45.5)
   DLCBL transformed from follicular lymphoma3 (9.1)
  T-cell lymphoma7 (21.2)
   Angioimmunoblastic T-cell lymphoma4 (12.1)
   Anaplastic large-cell lymphoma, T-/null-cell type2 (6.1)
   Mature T-cell lymphoma—not otherwise specified1 (3.0)
  Follicular lymphoma, grade 3b3 (9.1)
  Mantle cell lymphomac3 (9.1)
  Burkitt lymphoma—not otherwise specified2 (6.1)
 Ann Arbor classification, n (%)d,e
  Stage I1 (3.0)
  Stage II1 (3.0)
  Stage III8 (24.2)
  Stage IV20 (60.6)
Solid tumor cohort, n30
 Histology, n (%)d
  Breast cancer16 (25.4)
  Ovarian cancer4 (6.3)
  Endometrial cancer3 (4.8)
  Otherf7 (11.1)
 Breast cancer stage at initial diagnosis, n (%)g,h
  I3 (18.8)
  II3 (18.8)
  III5 (31.3)
  IV2 (12.5)
  • aRace not reported for 20 patients and missing for 1 patient.

  • bIncludes 1 grade 3a and 2 grade 3b.

  • cIncludes all variants: blastic, pleomorphic, and small cell.

  • dPercentages expressed as a proportion of the number of patients with lymphoma.

  • eAnn Arbor stage unknown for 3 patients.

  • fIncludes cervical cancer (n = 1), adenoid cystic carcinoma of the tongue (n = 1), head and neck cancer (n = 1), non–small cell lung cancer (n = 1), maxillary osteosarcoma (n = 1), prostate cancer (n = 1), and cancer of unknown primary site (n = 1).

  • gPercentages expressed as a proportion of the number of patients with breast cancer.

  • hStage missing for 3 patients.